Commercial and clinical-stage biopharmaceutical innovator Immuron Ltd (NASDAQ:IMRN, ASX:IMC) is addressing the unmet medical need posed by gastro-intestinal disease through its proprietary technology platform – along with its flagship assets already on the market and bringing in revenue.
Founded in 1994 and listed on the Australian Securities Exchange (ASX) since April 30, 1999, the biotech has since embarked on a much bigger journey with its listing on the Nasdaq in June 2017 allowing it to address gastro-intestinal health care on the global stage.
The power of antibodies
At its core, Immuron’s technology harnesses the power of polyclonal immunoglobulins (IgG) or antibodies derived from engineered hyper-immune bovine colostrum – cow’s milk – which mirror the action of human intravenous immunoglobulins.
The current market for these therapeutics generates more than US$16 billion in revenue annually in the US alone.
Immuron’s platform sets itself apart by producing orally active, highly specific immunoglobulins targeting enteric pathogens.
These antibodies are designed to deliver targeted action within the gastrointestinal (GI) tract without entering the bloodstream, a novel approach in the medical field.
Unlike human-derived IgG, bovine IgG thrives in the acidic environment of the stomach and resists digestion by GI tract enzymes, meaning it can deliver its full therapeutic potential directly to the pathogens present in the human gastrointestinal tract.
Broad spectrum of infectious diseases
This feature enables the development of treatments across a broad spectrum of infectious diseases, capable of blocking viruses or bacteria and neutralising the toxins they produce on mucosal surfaces like the gastrointestinal tract.
Travellers’ diarrhoea, caused by pathogenic bacteria and the toxins they produce in the digestive tract, and other GI disorders represent a considerable global health challenge.
The company hopes its proprietary technology will revolutionise the treatment paradigms for a range of GI disorders, including moderate to severe Campylobacteriosis, Clostridiodes difficile infections, Enterotoxigenic Escherichia coli (ETEC) infections and travellers’ diarrhoea.
Dairy derived
The dairy – and therefore already fit-for-human-consumption – origin of Immuron’s antibodies means a smoother regulatory pathway for commercialisation across prescription medications, medical foods, over-the-counter medicines, and dietary supplements.
Immuron manages risk by sourcing colostrum from countries like Australia and New Zealand, known for the safety and integrity of their dairy industries.
Beyond its clinical endeavours to develop these antibodies, Immuron has already successfully commercialised its flagship products, Travelan® and Protectyn®, both listed medicines on the Australian Register for Therapeutic Goods, giving the company an edge on the over-the-counter (OTC) front.
Travelan®, available in three global markets including Australia, Canada and the US, is an orally administered passive immunotherapeutic product designed to reduce the risk of travellers’ diarrhoea and minor gastrointestinal disorders.
Widely available
It is widely available in pharmacies across Australia and is also marketed in Canada as a natural health product and in the US as a dietary supplement for digestive tract protection.
Protectyn®, marketed as an immune supplement, aims to support healthy digestive function and liver health, and is available in practitioners' offices.
Immuron's journey from a pioneering start-up to a player on the global stage is testament to the dynamic nature of the Australian biopharmaceutical industry.
As the company continues to leverage its validated technology platform, its efforts not only contribute to the broader context of medical research and innovation and offer tangible solutions to improve global health outcomes – they are delivering real value to shareholders right now.